| Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link |
| 2020 | Ability of the post-operative ALBI grade to predict the outcomes of hepatocellular carcinoma after curative surgery | Cho W.-R.; Hung C.-H.; Chen C.-H.; Lin C.-C.; Wang C.-C.; Liu Y.-W.; Wu Y.-J.; Yong C.-C.; Chen K.-D.; YU-CHIEH TSAI ; Hu T.-H.; Tsai M.-C. | Scientific Reports | 9 | 8 | |
| 2012 | Altered prostate epithelial development in mice lacking the androgen receptor in stromal fibroblasts | Yu S.; Yeh C.-R.; Niu Y.; Chang H.-C.; YU-CHIEH TSAI ; Moses H.L.; Shyr C.-R.; Chang C.; Yeh S. | Prostate | 52 | 48 | |
| 2020 | Androgen receptor-regulated circFNTA activates KRAS signaling to promote bladder cancer invasion | Chen J.; Sun Y.; Ou Z.; Yeh S.; Huang C.-P.; You B.; YU-CHIEH TSAI ; Sheu T.-J.; Zu X.; Chang C. | EMBO Reports | 38 | 35 | |
| 2009 | Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy | Hsu F.-M.; Lee Y.-C.; Lee J.-M.; Hsu C.-H.; Lin C.-C.; YU-CHIEH TSAI ; Wu J.-K.; Cheng J.C.-H. | Annals of Surgical Oncology | 32 | 31 | |
| 2019 | Biological significance of GATA3, cytokeratin 20, cytokeratin 5/6 and p53 expression in muscle-invasive bladder cancer | Wang C.-C.; YU-CHIEH TSAI ; Jeng Y.-M. | PLoS ONE | 19 | 17 | |
| 2017 | CCN3 promotes epithelial-mesenchymal transition in prostate cancer via FAK/Akt/HIF-1�\-induced twist expression | Chen P.-C.; Tai H.-C.; Lin T.-H.; Wang S.-W.; Lin C.-Y.; Chao C.-C.; Yu H.-J.; YU-CHIEH TSAI ; Lai Y.-W.; Lin C.-W.; Tang C.-H. | Oncotarget | 12 | 10 | |
| 2019 | Correction to: Trichostatin A, a histone deacetylase inhibitor, induces synergistic cytotoxicity with chemotherapy via suppression of Raf/MEK/ERK pathway in urothelial carcinoma (Journal of Molecular Medicine, (2018), 96, 12, (1307-1318), 10.1007/s00109-018-1697-7) | Lin W.-C.; Hsu F.-S.; Kuo K.-L.; Liu S.-H.; Shun C.-T.; Shi C.-S.; Chang H.-C.; YU-CHIEH TSAI ; Lin M.-C.; Wu J.-T.; Kuo Y.; Chow P.-M.; Liao S.-M.; Yang S.-P.; Hong J.-Y.; Huang K.-H. | Journal of Molecular Medicine | 1 | 1 | |
| 2020 | Current and future aspect of immunotherapy for advanced renal cell carcinoma | Hsueh F.-J.; YU-CHIEH TSAI | Urological Science | 1 | 1 | |
| 2016 | Differences in toxicity and outcome associated with circadian variations between patients undergoing daytime and evening radiotherapy for prostate adenocarcinoma | Hsu F.-M.; Hou W.-H.; Huang C.-Y.; Wang C.-C.; Tsai C.-L.; YU-CHIEH TSAI ; Yu H.-J.; Pu Y.-S.; Cheng J.C.-H. | Chronobiology International | 22 | 23 | |
| 2009 | Down regulation of ABCD1 in human renal cell carcinoma | Hour T.-C.; Kuo Y.-Z.; Liu G.-Y.; Kang W.-Y.; Huang C.-Y.; YU-CHIEH TSAI ; Wu W.-J.; Huang S.-P.; Pu Y.-S. | International Journal of Biological Markers | 9 | 9 | |
| 2012 | Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells | Huang K.-H.; Kuo K.-L.; Chen S.-C.; Weng T.-I.; Chuang Y.-T.; YU-CHIEH TSAI ; Pu Y.-S.; Chiang C.-K.; Liu S.-H. | PLoS ONE | 29 | 24 | |
| 2012 | Down-regulation of PKC�a in renal cell carcinoma and its clinicopathological implications. | Pu Y.S.; Huang C.Y.; Chen J.Y.; Kang W.Y.; Lin Y.C.; Shiu Y.S.; Chuang S.J.; Yu H.J.; Lai M.K.; YU-CHIEH TSAI ; Wu W.J.; Hour T.C. | Journal of biomedical science | 14 | 12 | |
| 2020 | Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial | Powles T.; van der Heijden M.S.; Castellano D.; Galsky M.D.; Loriot Y.; Petrylak D.P.; Ogawa O.; Park S.H.; Lee J.-L.; De Giorgi U.; B?gemann M.; Bamias A.; Eigl B.J.; Gurney H.; Mukherjee S.D.; Fradet Y.; Skoneczna I.; Tsiatas M.; Novikov A.; Su?rez C.; Fay A.P.; Duran I.; Necchi A.; Wildsmith S.; He P.; Angra N.; Gupta A.K.; Levin W.; Bellmunt J.; van der Heijden M.S.; Lee J.L.; Eigl B.J.; Mukherjee S.D.; Suarez C.; Westgeest H.; Flechon A.; Ou Y.-C.; Park I.; Matveev V.; P?rez-Valderrama B.; Cheng S.; Frank S.; Anido U.; Hamzaj A.; Retz M.; Sridhar S.; Scagliotti G.V.; Voortman J.; Alekseev B.; Alyasova A.; Komyakov B.; Dumez H.; Pavic M.; Kimura G.; Mizokami A.; Osanto S.; Arranz J.A.; Piersma D.; Shin S.J.; Karyakin O.; Delgado I.; Gonzalez J.L.; Pang S.-T.; Tran A.; Lipatov O.; Su W.-P.; Flaig T.; Alva A.; Park Kyong H.; Kopyltsov E.; Almagro E.; Domenech M.; Chang Y.-H.; Sautois B.; Ravaux A.; Aravantinos G.; Georgoulias V.; Mulder S.; Kim Y.J.; Kater F.; Chevreau C.; Tagawa S.; Zalewski P.; Joly F.; Hatiboglu G.; Gianni L.; Morelli F.; Tambaro R.; Hashimoto Y.; Nosov A.; Font A.; Rodriguez-Vida A.M.; Jones R.; Vasudev N.; Srinivas S.; Zhang J.; Gil T.; Finch D.; Grimm M.-O.; Su Y.-L.; Chowdhury S.; Hocking C.; Plas E.; North S.; Jensen N.V.; Theodore C.; Imkamp F.; Peer A.; Kobayashi T.; Sakai H.; Sassa N.; Yoshimura K.; Aarts M.; Ferreira Castro A.; Topuzov M.; Rodriguez J.F.; Vazquez F.J.; YU-CHIEH TSAI ; Crabb S.; Hussain S.; Bendell J.; Gross-Goupil M.; Gwenaelle G.; Berger R.; Statsenko G.; Evans L.; Drakaki A.; Somer B.; Davis I.; Lynam J.; Borges G.; Dettino A.; Fay A.P.; Martins G.; Zucca L.E.; Agerbaek M.; Kalofonos H.; Rosenbaum E.; Enokida H.; Kikukawa H.; Nishimura K.; Tamada S.; Uemura M.; Lopez Y.; Gietema J.; Slojewski M.; Fernandes I.; Smolin A.; Mazhar D.; Kalebasty A.R.; Carthon B.; Loidl W.; Franke F.; Girotto G.; Alimohamed N.; Macfarlane R.; Pappot H.; Niegisch G.; Mavroudis D.; Sella A.; Porta C.; Ebara S.; Nakamura M.; Obara W.; Okuno N.; Shinohara N.; Sugimoto M.; Suzuki A.; Tokuda N.; Uemura H.; Yamaguchi A.; Ramirez F.; Rozanowski P.; Wiechno P.; Keam B.; Kislov N.; Plaksin D.; Cicin I.; Kumar S.; Galsky M.D.; Petrylak D.P.; Rosales J.; Vaishampayan U.; Culine S.; Papandreou C.; Nara T.; Erman M.; Kreiger L.; Janoski J.; Rosa D.; Siqueira M.; Canil C.; Sengelov L.; Tourani J.-M.; Arai G.; Hashine K.; Kawakita M.; Nakaigawa N.; Nomi H.; Shiina H.; Suzuki H.; Yonese J.; Kuri R.; Macedo E.; Rivera S.; Villalobos Prieto A.; Polakiewicz-Gilowska A.; Zaucha R.; Lopes F.; Ponomarev R.; Pomerantz M.; Shariat S.; Luk C.; Lesniewski-Kmak K. | The Lancet Oncology | 122 | 108 | |
| 2017 | Effects of short forest bathing program on autonomic nervous system activity and mood states in middle-aged and elderly individuals | Yu C.-P.; Lin C.-M.; Tsai M.-J.; YU-CHIEH TSAI ; Chen C.-Y. | International Journal of Environmental Research and Public Health | 76 | 67 | |
| 2014 | Estrogen receptor alpha prevents bladder cancer development via INPP4B inhibited Akt pathway in vitro and in vivo | Hsu I.; Yeh C.-R.; Slavin S.; Miyamoto H.; Netto G.J.; YU-CHIEH TSAI ; Muyan M.; Wu X.-R.; Messing E.M.; Guancial E.A.; Yeh S. | Oncotarget | 51 | 46 | |
| 2007 | Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study | Lin C.-C.; Hsu C.-H.; Huang C.-Y.; Keng H.-Y.; YU-CHIEH TSAI ; Huang K.-H.; Cheng A.-L.; Pu Y.-S. | Anti-Cancer Drugs | 31 | 28 | |
| 2008 | Improved local control by surgery and paclitaxel-based chemoradiation for esophageal squamous cell carcinoma: Results of a retrospective non-randomized study | Hsu F.-M.; Lin C.-C.; Lee J.-M.; Chang Y.-L.; Hsu C.-H.; YU-CHIEH TSAI ; Lee Y.-C.; Cheng J.C.-H. | Journal of Surgical Oncology | 29 | 27 | |
| 2009 | Induction Cisplatin and Fluorouracil-Based Chemotherapy Followed by Concurrent Chemoradiation for Muscle-Invasive Bladder Cancer | Lin C.-C.; Hsu C.-H.; Cheng J.C.; Huang C.-Y.; YU-CHIEH TSAI ; Hsu F.-M.; Huang K.-H.; Cheng A.-L.; Pu Y.-S. | International Journal of Radiation Oncology Biology Physics | 23 | 18 | |
| 2015 | MLN4924 synergistically enhances cisplatin-induced cytotoxicity via jnk and bcl-xl pathways in human urothelial carcinoma | Ho I.-L.; Kuo K.-L.; Liu S.-H.-.; Chang H.-C.; Hsieh J.-T.; Wu J.-T.; Chiang C.-K.; Lin W.-C.; YU-CHIEH TSAI ; Chou C.-T.; Hsu C.-H.; Pu Y.-S.; Shi C.-S.; Huang K.-H. | Scientific Reports | 30 | 30 | |
| 2015 | MLN4924, a novel protein neddylation inhibitor, suppresses proliferation and migration of human urothelial carcinoma: In vitro and in vivo studies | Kuo K.-L.; Ho I.-L.; Shi C.-S.; Wu J.-T.; Lin W.-C.; YU-CHIEH TSAI ; Chang H.-C.; Chou C.-T.; Hsu C.-H.; Hsieh J.-T.; Chang S.-C.; Pu Y.-S.; Huang K.-H. | Cancer Letters | 41 | 43 | |
